ProCE Banner Activity

CLL Treatment: Cutting Though the Noise to Address Educational Needs

Clinical Thought

In this commentary, Dr Jeff Sharman reviews data and provides expert recommendations in response to a survey highlighting ongoing educational needs focused on current and emerging uses of BTK inhibitors in treating patients with CLL.

Released: April 25, 2022

Expiration: April 24, 2023

Share

Faculty

Jeffrey P. Sharman

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

Jeffrey P. Sharman, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly.